Financial Data and Key Metrics Changes - The 2022 net sales guidance for INGREZZA is projected to be between $1.25 billion and $1.35 billion, marking the first time the company has provided annual sales guidance [14][19] - The GAAP operating expense range for 2022 is estimated to be between $1.1 billion and $1.15 billion, with a significant increase in sales force expansion and direct-to-consumer advertising [19][20] Business Line Data and Key Metrics Changes - INGREZZA's Q4 performance showed a total prescription growth of 8% sequentially and 32% year-over-year, marking the third consecutive quarter of growth during the pandemic [23][27] - The company has expanded its sales force to over 350 members, focusing on psychiatry, neurology, and long-term care [29] Market Data and Key Metrics Changes - The total addressable market for tardive dyskinesia (TD) in the U.S. is estimated at 600,000 patients, with only about 25% currently diagnosed [108][110] - The use of antipsychotics continues to grow, leading to an increase in the TD patient population, with 70 million prescriptions written in the past year [115][116] Company Strategy and Development Direction - The company aims to accelerate growth through a combination of expanding its sales force and enhancing its commercial initiatives, including a direct-to-consumer advertising campaign [17][29] - The R&D pipeline includes 12 mid- to late-stage clinical programs, with plans to submit a supplemental new drug application for valbenazine for Huntington's disease in the second half of 2022 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the external environment improving, which is expected to positively impact patient access and sales [28][69] - The company acknowledges the challenges posed by COVID-19 but believes that the reopening of clinics and increased patient visits will drive growth in the latter half of 2022 [9][16] Other Important Information - The company is focused on addressing the unmet medical needs in neurology and psychiatry, with a strong emphasis on innovative therapies [42][100] - The company plans to continue exploring business development opportunities to enhance its pipeline and market presence [99] Q&A Session Summary Question: Can you give us some sense of what would be proof of concept for essential tremor? - The proof-of-concept study includes several endpoints, with a primary focus on tremor amplitude measured by accelerometer, and a statistically significant difference is sought [48] Question: How does the demand growth for INGREZZA compare to pre-COVID levels? - Prior to the pandemic, the company experienced a growth trajectory of a couple of hundred million dollars per year, and a 20% midpoint growth in guidance aligns with that performance [51][52] Question: Is your guidance impacted by inventory stocking for INGREZZA? - The guidance reflects underlying demand for INGREZZA sales, and inventory fluctuations are expected to net out over the year [56][58] Question: What are the expectations for long-term care opportunities? - Long-term care represents a significant incremental opportunity, with several million people in facilities potentially treated with antipsychotics that cause TD [103][104] Question: How fast is the total addressable TD market growing? - The TD population is growing due to the increased use of antipsychotics, with estimates rising from around 500,000 to 600,000 patients over the past five years [116]

Company Vision and Purpose - The company's vision is understanding the brain to treat the body, relieving patient suffering, and taking responsibility beyond medicine[5] - The company's purpose is to relieve suffering for people with great needs, but few options[6] Commercial Products and Pipeline - Commercial products are fueling pipeline investment, focusing on neurology, neuroendocrinology, and psychiatry[7,9] - The company achieved approximately $1 billion in annual sales in 35 years[13] - The company has a strong financial position with approximately $13 billion in cash and investments as of September 30, 2021[13] - The company has 13 total mid- to late-stage programs[13] Pipeline Focus and Development - The company is tackling difficult and undertreated diseases in neuroscience, including Parkinson's Disease, Tardive Dyskinesia, and others[15,16] - Development programs are dominated by mid- and late-stage studies[56] - There are approximately 500000 undiagnosed and untreated patients in the US with TD[13] Upcoming Milestones - Significant milestones this year include valbenazine sNDA filing for Chorea in Huntington Disease and Phase 2 data for NBI-827104 in CSWS and Essential Tremor[59] - 2023 clinical activities & milestones include Crinecerfont registrational top-line data for CAH in adults and pediatrics, and valbenazine sNDA approval for Chorea in Huntington Disease[60]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2021 Earnings Conference Call November 1, 2021 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer and Director Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Neena Garg - Citi Paul Matteis - Stifel Carter Gould - Barclays Tazeen Ahmad - Bank of America Phil Nadeau - Cowen Company Anupam Rama - J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdictio ...

| --- | --- | --- | --- | |----------------|------------------------------------------------------|-------|--------------------------------| | | | | | | | Advancing Life-Changing Discoveries in Neuroscience | | Q2 2021 Corporate Presentation | | neurocrine.com | | | August 3, 2021 Nasdaq: NBIX | Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2021 Results Conference Call August 3, 2021 4:30 PM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Phil Nadeau - The Cowen Company Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Brian Skorney - Baird Jay Olson - Oppenh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Paul Matteis - Stifel Phil Nadeau - Cowen & Company Brian Skorney - Baird Josh Schimmer - Evercore ISI Neena Bitritto-Garg - Ci ...

| --- | --- | --- | --- | --- | |----------------|------------------------------------------------------|-------|-------|--------------------------------------------| | | | | | | | | Advancing Life-Changing Discoveries in Neuroscience | | | Q1 2021 Corporate Presentation May 5, 2021 | | neurocrine.com | | | | Nasdaq: NBIX | Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertaint ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...